Yes, of course. However the Dollar Foot-print of the complete pipeline of CTIX compared to the one trick pony of Pharmasset's Hepatitis C compound is what I'm basing a much higher pps buyout on.
Eighty percent of just Kevetrin for cancer vs. Hepatitis C - is huge. Then add the rest. $160.00 a share then can walk in the door and take a seat. Perhaps Opening Bid.